Weimer Katja, Enck Paul
Department of Psychosomatic Medicine, University Hospital Tübingen, Tübingen, Germany.
Handb Exp Pharmacol. 2014;225:237-72. doi: 10.1007/978-3-662-44519-8_14.
Many study designs and design variants have been developed in the past to either overcome or enhance drug-placebo differences in clinical trials or to identify and characterize placebo responders in experimental studies. They share many commonalities as well as differences that are discussed here: the role of deception and ethical restrictions, habituation effects and the control of the natural course of disease, assay sensitivity testing and effective blinding, acceptability and motivation of patients and volunteers, and the development of individualized medicine. These are fostered by two opposite strategies: utilizing the beneficial aspects of the placebo response-and avoiding its negative counterpart, the nocebo effect-in medical routine for the benefit of patients, and minimizing-by controlling-the negative aspects of the placebo effect during drug development.
过去已经开发出许多研究设计和设计变体,以克服或增强临床试验中药物与安慰剂的差异,或在实验研究中识别和表征安慰剂反应者。它们有许多共同点和差异,在此进行讨论:欺骗的作用和伦理限制、习惯化效应和疾病自然进程的控制、分析灵敏度测试和有效的盲法、患者和志愿者的可接受性和动机,以及个性化医学的发展。这是由两种相反的策略推动的:在医疗常规中利用安慰剂反应的有益方面——并避免其负面对应物,即反安慰剂效应——以造福患者;在药物开发过程中通过控制来最小化安慰剂效应的负面影响。